Healthcare Industry News: Ampion
News Release - February 26, 2007
ReGen Biologics Data Presented in San DiegoFRANKLIN LAKES, N.J.--(HSMN NewsFeed)--Data derived from ReGen Biologics' pivotal meniscus implant trial was presented last week during the American Academy of Orthopaedic Surgeons (AAOS) meeting. The podium presentation, "New Tissue Generated by the Collagen Meniscus Implant (CMI) Leads to Increased Activity Levels After Two Years," was given during Specialty Day, a day set aside for programs produced by the Board of Specialty Societies. It was part of an AOSSM (American Orthopaedic Society for Sports Medicine) scientific session focused on the meniscus.
The panel was moderated by Kurt Spindler, M.D. of Nashville and co-moderated by Benjamin Shaffer, M.D. of Washington, D.C. The CMI data, authored by William Rodkey, DVM and Karen Briggs, MPh, showed a significant correlation between change (increase) in Tegner activity levels over 2 years and percent total meniscus tissue in patients who receive the CMI implant and have greater than 50% total meniscus tissue.
The study confirms the importance of preserving as much meniscus tissue as possible at the time of meniscus treatment, and supports the potential positive benefits of using the CMI as a scaffold to allow the patient's own tissue to fill the void left by partial meniscectomy. A copy of the abstract can be found on the ReGen Biologics website at http://www.regenbio.com/en/news/default.mspx, within the AAOS event listing.
With more than 29,000 members, the American Academy of Orthopaedic Surgeons (www.aaos.org) is the premier not-for-profit organization that provides education programs for orthopaedic surgeons and allied health professionals, chAmpions the interests of patients and advances the highest quality musculoskeletal health. Orthopaedic surgeons and the Academy are the authoritative sources of information for patients and the general public on musculoskeletal conditions, treatments and related issues. This year's meeting had a pre-registration of over 10,400 physicians, including nearly 3000 from outside the United States.
About ReGen Biologics, Inc.:
ReGen Biologics is a global orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products. ReGen's patented collagen scaffold technology includes applications in orthopedics, general surgery, spine, cardiovascular and drug delivery. The Company's first approved product using its collagen scaffold technology is the CMI(TM), a meniscus application cleared for sale in Europe and marketed through the Company's European subsidiary, ReGen Biologics AG. ReGen has submitted a 510(k) to the FDA in the U.S. for clearance of the CMI. ReGen Biologics is headquartered in Franklin Lakes, NJ and operates a manufacturing plant in Redwood City, CA. For more information on ReGen, visit www.regenbio.com.
Source: ReGen Biologics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.